What the research found

Dr. Castro's work centres on a conceptual framework called "inflammatory fidelity"—the idea that aging involves a shift in the balance between different types of inflammatory activity, rather than simply "too much inflammation." Using transcriptomic data spanning development through old age, his team identified two distinct inflammatory circuits: one that's prominent early in life but declines with age, and another that accumulates over time. They developed a fidelity score by comparing the activity of regeneration-linked inflammatory pathways to those associated with aging and chronic disease.

This score appears to track biological state. It drops in aging, chronic disease, and fibrosis; it rises in regenerative contexts and in patterns linked to longer lifespan. The concept suggests that inflammation's role in aging isn't simply about quantity, but about which inflammatory processes are active and which have faded—losing the ability to repair and adapt while retaining the processes that drive degeneration.

Why it matters for you

If inflammatory fidelity holds up, it reframes how you might think about anti-inflammatory interventions. Blunt suppression of all inflammatory signalling could backfire if it silences regenerative processes you actually need—wound healing, immune defence, muscle repair after training. This aligns with emerging evidence that some NSAIDs or immunosuppressive approaches may impair adaptation.

For MyKine users tracking biomarkers like CRP, IL-6, or TNF-α, the framework suggests that raw inflammatory levels alone may miss the picture. Two people with identical CRP could have very different inflammatory profiles at the circuit level. Similarly, training stimulus, sleep disruption, or infection recovery all modulate inflammation—but the quality of that response (fidelity) may matter more than the magnitude. A therapeutic intervention that restores youthful regenerative inflammation while dampening senescent inflammation would theoretically outperform one that just lowers inflammation across the board.

Caveats

  • Unpublished concept: The inflammatory fidelity framework has not yet undergone peer review; the scoring system is presented conceptually but not yet validated in humans.
  • Transcriptomic data only: The work relies on gene expression patterns, not direct measurement of functional inflammatory circuits or protein activity in living organisms.
  • Complexity of translation: A score that correlates with lifespan and regeneration in transcriptomic datasets may not translate directly to actionable clinical targets or biomarkers you can measure in blood.
  • Early-stage mechanistic work: No evidence is presented that modulating fidelity in humans extends lifespan or reverses aging; the framework is explanatory rather than therapeutic at this stage.